Future studies should focus on studying the tumor-initiating ability of ET-treated Cx43-KO S1 cells, and the tumor-enhancing ability of ET-treated MDA-MB-231 and MCF-7 cells in vivo as compared to their untreated counterparts. This evidence concerns the gene GJA1 and neoplasm.